---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-010231"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2022-03-15T23:59:59+00:00"
generated_at: "2026-06-26T22:47:59.973718+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q4/FY2021 net loss $24.9M/$72.3M; three bezuclastinib trials enrolling

## Summary
- Cash $219.7M at Dec 31, 2021, sufficient to fund operations into 2024.
- APEX Phase 2 trial in AdvSM on track for initial data in H1 2022; SUMMIT (NonAdvSM) and PEAK (GIST) actively enrolling.
- Raised ~$38M via ATM in Q4 2021; shares sold at $9.25-$10.30.
- R&D expenses $55.9M in FY2021 vs $25.7M in FY2020, driven by trial start-up costs and research team expansion.
- Appointed Dr. Zamaneh Mikhak as SVP Head of Clinical Development; R&D Investor Event on April 8, 2022.

## SEC filing metadata
- accession: 0001564590-22-010231
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2022-03-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000156459022010231/0001564590-22-010231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000156459022010231/cogt-8k_20220315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-010231
- JSON: https://secwatch.observer/filing/0001564590-22-010231.json
- Plain text: https://secwatch.observer/filing/0001564590-22-010231.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.